Newer Blood Thinner Brilinta Exceeds Plavix For Cardiac Bypass Surgery Patients.
In a trying out comparing two anti-clotting drugs, patients given Brilinta before cardiac detour surgery were less tenable to die than those given Plavix, researchers found. Both drugs ban platelets from clumping and forming clots, but Plavix, the more popular drug, has been linked to potentially threatening side effects in cancer patients.
In addition, some people don't metabolize it well, making it less effective. "We did meditate about a 50 percent reduction in mortality in these patients, who took Brilinta, but without any multiplication in bleeding complications," Dr Claes Held, an associate professor of cardiology at the Uppsala Clinical Research Center at Uppsala University in Sweden and the study's hero researcher, said during an afternoon host conference Tuesday.
So "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the capacity need for bypass surgery, is more effective than clopidogrel (Plavix) in preventing cardiovascular and totality mortality without increasing the risk of bleeding". A danger with any anti-platelet medicament is the risk of uncontrolled bleeding, which is why these drugs are stopped before patients undergo surgery.
Held was scheduled to make known the results Tuesday at the American College of Cardiology's annual meeting in Atlanta. For the study, Held and colleagues looked at a subgroup of 1261 patients in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The researchers found that 10,5 percent of the patients given Brilinta supplementary aspirin before surgery had a callousness attack, achievement or died from heart disease within a week after surgery. Among patients given Plavix with an increment of aspirin, 12,6 percent had the same adverse outcomes.
Patients taking Brilinta had a total number death rate of 4,6 percent, compared with 9,2 percent for patients taking Plavix. In addition, the cardiovascular decease rates were 4 percent among patients taking Brilinta and 7,5 percent amidst those taking Plavix. When Held's team looked at each group individually, they found no statistically significant idiosyncrasy for heart attack and stroke and no significant difference in major bleeding from the bypass operation itself. The two drugs employment in different ways.
Showing posts with label plavix. Show all posts
Showing posts with label plavix. Show all posts
Thursday, 14 March 2019
Sunday, 10 March 2019
Austrian Scientists Have Determined The Effect Of Morphine On Blood Coagulation
Austrian Scientists Have Determined The Effect Of Morphine On Blood Coagulation.
Morphine appears to grind the effectiveness of the commonly hand-me-down blood-thinning narcotic Plavix, which could hamper emergency-room efforts to treat heart attack victims, Austrian researchers report. The conclusion could create serious dilemmas in the ER, where doctors have to weigh a nucleus patient's intense pain against the need to break up and prevent blood clots, said Dr Deepak Bhatt, regulatory director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center, in Boston. "If a dogged is having crushing heart pain, you can't just inform them to tough it out, and morphine is the most commonly used medication in that situation," said Bhatt, who was not active in the study.
And "Giving them morphine is the humane thing to do, but it could also create delays in care". Doctors will have to be mainly careful if a heart attack patient needs to have a stent implanted. Blood thinners are judgemental in preventing blood clots from forming around the stent. "If that setting is unfolding, it requires a little bit of extra thought on the part of the physician whether they want to give that full slug of morphine or not".
About half of the 600000 stent procedures that bolt place in the United States each year surface as the result of a heart attack, angina or other acute coronary syndrome. The Austrian researchers focused on 24 flourishing people who received either a dose of Plavix with an injection of morphine or a placebo drug. Morphine delayed the cleverness of Plavix (clopidogrel) to thin a patient's blood by an regular of two hours, the researchers said.
Morphine appears to grind the effectiveness of the commonly hand-me-down blood-thinning narcotic Plavix, which could hamper emergency-room efforts to treat heart attack victims, Austrian researchers report. The conclusion could create serious dilemmas in the ER, where doctors have to weigh a nucleus patient's intense pain against the need to break up and prevent blood clots, said Dr Deepak Bhatt, regulatory director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center, in Boston. "If a dogged is having crushing heart pain, you can't just inform them to tough it out, and morphine is the most commonly used medication in that situation," said Bhatt, who was not active in the study.
And "Giving them morphine is the humane thing to do, but it could also create delays in care". Doctors will have to be mainly careful if a heart attack patient needs to have a stent implanted. Blood thinners are judgemental in preventing blood clots from forming around the stent. "If that setting is unfolding, it requires a little bit of extra thought on the part of the physician whether they want to give that full slug of morphine or not".
About half of the 600000 stent procedures that bolt place in the United States each year surface as the result of a heart attack, angina or other acute coronary syndrome. The Austrian researchers focused on 24 flourishing people who received either a dose of Plavix with an injection of morphine or a placebo drug. Morphine delayed the cleverness of Plavix (clopidogrel) to thin a patient's blood by an regular of two hours, the researchers said.
Saturday, 6 February 2016
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Higher doses of the blood-thinner Plavix were no better at preventing bravery attacks, blood clots or obliteration than the yardstick lower dose in patients who had received artery-opening stents, renewed research shows. The higher dose - understudy the usual amount - was tested in patients with "high platelet reactivity," meaning they failed to reply to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have dirty platelet reactivity and who have had stents inserted to prop open blocked arteries.
But the supplemental study "doesn't support" physicians using the higher, 150-milligram dose of Plavix after stenting, according to sanctum lead author Dr Matthew Price, who presented the findings Tuesday at the annual congress of the American Heart Association in Chicago. So, the study leaves an important question unanswered: How to review heart patients who don't respond well to Plavix? "It remains erratic to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn. "It's an effective study to have done but the key issues are that a significant proportion of the patients remained with weighty platelet reactivity even after being on the higher dose".
Previous, smaller studies had indicated that Plavix might have more of an effect if the quantity was doubled. "Platelet reactivity varies widely," noted Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a gamy reactivity standing is associated with poorer outcomes after angioplasty and/or stenting. But until now, a ret rise in the dose of Plavix "has not been tested in a large randomized clinical trial".
Subscribe to:
Posts (Atom)